Risk & Audit Management Software Directory

It refers to platforms used by QA and regulatory teams to document risk assessments, track audit findings, manage CAPAs, and oversee supplier qualification across GxP environments. Unlike general enterprise risk tools, these systems are built around regulated workflows — controlled signatures, validated states, and traceable evidence trails — so that inspection-ready documentation can be produced for FDA, EMA, or notified body reviews without reconstructing history from disparate sources.

Key considerations include validation burden, configurability of risk scoring models (FMEA, ICH Q9), depth of audit workflow coverage from scheduling through CAPA closure, and integration with adjacent QMS modules such as document control, training, and deviation management. Buyers should also assess supplier qualification capabilities, electronic signature compliance, and whether the system accommodates both internal audits and external inspections without heavy customisation.

GxP coverage is near-universal across the category, with 21 CFR Part 11 support common given the need for electronic signatures and audit trails on risk and audit records. ISO 13485 appears where medical device manufacturers are the primary users, reflecting design risk and supplier control requirements. EU MDR coverage is narrower and tends to cluster in vendors targeting device makers handling post-market surveillance obligations.

A full QMS spans document control, training, change management, deviations, and complaints alongside risk and audit. Dedicated risk and audit tools focus specifically on hazard identification, risk register maintenance, audit planning, finding tracking, and supplier evaluation. Many organisations adopt them as modules within a wider quality suite, while others deploy point solutions when their existing QMS lacks depth in supplier audit scheduling or quantitative risk analysis.

Yes — almost all platforms in this space are delivered as SaaS, with on-premise options now uncommon. This reflects shifting validation practices, vendor-managed qualification packages, and the operational preference for centralised audit data across multi-site organisations. Teams handling highly sensitive data or operating under specific data residency constraints occasionally retain on-premise deployments, but the direction of travel across pharma, biotech, and device manufacturers is clearly cloud-first.